BPC-157 Oral (Tablets 500MCG)

What is BPC-157 Oral?

BPC-157 Oral (500mcg tablets) is an orally administered formulation of BPC-157 (Body Protective Compound-157) — notable because BPC-157 is one of the very few peptides with demonstrated stability in gastric acid and meaningful oral bioavailability. While most peptides are rapidly degraded by stomach acid and digestive enzymes, BPC-157's unique structure — derived from human gastric juice — confers significant resistance to gastric degradation.

Mechanism of Action

BPC-157's mechanisms are identical to the injectable form: VEGF-driven angiogenesis, GH receptor upregulation, eNOS activation, and FAK-paxillin pathway stimulation. The oral route of administration changes bioavailability patterns — oral BPC-157 demonstrates particularly direct and potent effects on the gastrointestinal tract given direct exposure to GI mucosa during transit.

Why Oral BPC-157 for GI Applications?

For research specifically targeting gastrointestinal pathology — inflammatory bowel disease, gastric ulcers, intestinal permeability, mucosal healing — oral administration may provide superior local concentration at the site of pathology compared to systemic (injectable) delivery. This direct mucosal exposure may be the optimal route for studying BPC-157's extensive documented GI-protective effects.

Key Research Findings

Research comparing oral and injectable BPC-157 shows comparable systemic tissue healing effects while oral administration demonstrates particularly pronounced GI effects due to direct mucosal contact. Studies in IBD and gastric ulcer models consistently show oral BPC-157 produces rapid mucosal healing with an excellent safety profile across hundreds of studies.

*For research use only. Not for human consumption.*